drugset / Trial / NCT05065567

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

NCT05065567

Phase 3 Terminated 32 enrolled Corewell Health South
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.

Timeline

Start
2021-08-30
Primary completion
2023-11-20
Completion
2023-11-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Droperidol Small molecule 2.5 mg Intravenous
Comparator Haloperidol Other / unclassified 5 mg Intramuscular
Comparator Ondansetron Other / unclassified 8 mg Intravenous